Get startedLog in
    Picture of Vanda Pharmaceuticals logo

    VNDA — Vanda Pharmaceuticals News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousSmall CapNeutral
    All News

    Brief: Vanda Pharmaceuticals Announces U.S. Commercial Availability Of Nereus™ (Tradipitant), The First New Pharmacologic Treatment For People With Motion Sickness In More Than 40 Years

    Picture of Vanda Pharmaceuticals logoVanda Pharmaceuticals
    04/05/2026 13:08
    May 4 (Reuters) - Vanda Pharmaceuticals Inc VNDA.O:

VANDA PHARMACEUTICALS ANNOUNCES U.S. COMMERCIAL AVAILABILITY OF NEREUS™ (TRADIPITANT), THE FIRST NEW PHARMACOLOGIC TREATMENT FOR PEOPLE WITH MOTION SICKNESS IN MORE THAN 40 YEARS

VANDA PHARMACEUTICALS INC - NEREUS AVAILABLE AT $85 PER DOSE CASH-PAY

Source text: ID:nPnb6kJf2a

Further company coverage: VNDA.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Vanda Pharmaceuticals

    See all news